Sandra Rutzner

Safety and efficacy of single cycle induction treatment with cisplatin/docetaxel/ durvalumab/tremelimumab in locally advanced HNSCC: first results of CheckRad-CD8

Markus Hecht, Antoniu‐Oreste Gostian, Markus Eckstein et al. · Journal for ImmunoTherapy of Cancer · 2020 · 87 citations · Full text

Pharmacy, Oncology, Pharmacotherapy +14

Prospective development and validation of a liquid immune profile-based signature (LIPS) to predict response of patients with recurrent/metastatic cancer to immune checkpoint inhibitors

Jian‐Guo Zhou, Anna-Jasmina Donaubauer, Benjamin Frey et al. · Journal for ImmunoTherapy of Cancer · 2021 · 63 citations · Full text

Life Sciences, Immunology, Oncology +17

R0 resection following chemo (radio)therapy improves survival of primary inoperable pancreatic cancer patients. Interim results of the German randomized CONKO-007± trial

Rainer Fietkau, Robert Grützmann, Uwe A. Wittel et al. · Strahlentherapie und Onkologie · 2020 · 60 citations · Full text

Medicine, Oncology, Surgery +15

Induction chemoimmunotherapy followed by CD8+ immune cell-based patient selection for chemotherapy-free radioimmunotherapy in locally advanced head and neck cancer

Markus Hecht, Markus Eckstein, Sandra Rutzner et al. · Journal for ImmunoTherapy of Cancer · 2022 · 45 citations · Full text

Medicine, Oncology, Radiation Oncology +15

Prospective evaluation of the prognostic value of immune-related adverse events in patients with non-melanoma solid tumour treated with PD-1/PD-L1 inhibitors alone and in combination with radiotherapy

Claudia Schweizer, Philipp Schubert, Sandra Rutzner et al. · European Journal of Cancer · 2020 · 37 citations · Full text

Life Sciences, Immunology, Oncology +17